Australian-Singaporean regenerative medicine company Osteopore Limited (ASX: OSX; Osteopore or the Company) – a global leader in 3D-printed biomimetic and bioresorbable implants – is excited to announce the signing of a collaboration agreement by its subsidiary Osteopore International Pte Ltd and NASDAQ-listed biopharmaceutical company CytoMed Therapeutics Limited (CytoMed).
Highlights
- Osteopore (OSX) signs a collaboration agreement with CytoMed Therapeutics Limited (CytoMed) to combine CytoMed’s mesenchymal stem cells (MSCs) with OSX’s bioresorbable scaffolds.
- NASDAQ-listed CytoMed (NASDAQ: GDTC) is a leading-edge biopharmaceutical company specialising in cancer therapeutics.
- CytoMed’s cGMP lab manufactures clinical-grade allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs).
- UC-MSCs are highly effective for targeted tissue regeneration and have demonstrated a strong clinical track record.
- The agreement expands Osteopore into the scaffold-based cell therapy market, which is projected to surpass USD 4.39b by 2034.
NASDAQ-listed CytoMed (NASDAQ: GDTC) is a Singapore-based biopharmaceutical company, which seeks to leverage its proprietary technology to develop donor-derived cell-based allogeneic therapies for cancer and age-related degenerative diseases. Recently, they secured approval from Singapore’s Health Sciences Authority (HSA) for Phase 1 clinical trials at Singapore’s National University Hospital (NUH).
In addition, CytoMed recently gained access to UC-MSCs through an acquisition of Cord Blood Banking License and Assets.
MSCs have demonstrated a strong clinical track record due to their mature isolation protocols, safety, and immunomodulatory properties. Based on a report published in 2021, more than 1,100 clinical trials had been registered in the areas of traumatology, neurology, cardiology, and neurology tissues and mitigating inflammation – more importantly, all of them reported positive results with no serious adverse events.
As research continues to progress, MSCs are emerging as a key element in creating advanced therapies that enhance the body’s natural healing power. Their application demonstrates significant potential for transforming healthcare approaches to repairing damaged tissues and improving patient outcomes.
OSX Chairman Mark Leong is an independent non-executive director of CytoMed.
Under the scope of the 18-month agreement, Osteopore and CytoMed will set up a Technology Advisory Committee (TAC) comprising one nominee from each party to assess co-development and resource utilisation opportunities.
Subsequently, Osteopore and CytoMed may seek third-party funding to support growth and development opportunities in scaffold-based cell therapy.
Key highlights of the collaboration agreement:
- Capabilities and expertise: The collaboration will leverage Osteopore’s proprietary scaffold-based technology and CytoMed’s cell-based therapeutic capabilities.
- Joint development: The parties will work together to co-design scaffold-based cellular products.
- Clinical testing: The collaboration will pave the way for pre-clinical studies to validate and progress the development of scaffold-based cellular products.
- Commercialisation strategy: Leveraging their networks and resources, the parties will collaborate on the commercialisation runway for scaffold-based cellular products.
Commenting on Osteopore’s goal to revolutionise tissue regeneration by harnessing MSCs and scaffold-based cell therapy, Chairman Mark Leong stated:
“Together with our innovative scaffolds, MSCs will play a pivotal role in tissue repair, offering exceptional safety, accessibility, and the power to speed up healing and recovery. This is the future of tissue regeneration, where structural innovation meets cellular healing.
“The integration of clinical-grade UC-MSCs with our scaffold technology, combined with our shared commitment to regenerative medicine, creates powerful synergies that can significantly enhance patient outcomes,” stated Mr. Leong.
Commenting on the synergies created by CytoMed’s revolutionary collaboration with Osteopore, Chairman Peter Choo said:
“This collaboration marks a significant step forward in CytoMed’s expanding focus on regenerative medicine and longevity.
“Osteopore’s proven scaffold technology aligns perfectly with our goal of leveraging our high-quality UC-MSCs to drive better outcomes across a broad range of promising applications,” said Mr Choo.
